Sloan-Kettering - Adam Olshen: Publications

1. Thompson EA, Lin S, Olshen AB, Wijsman EM. Monte Carlo segregation and linkage analysis of a large hypercholesterolemia pedigree. Genet Epidemiol 1993;10:677‑682.

2. Olshen AB, Wijsman EM. PAP vs MIXD: fitting the mixed model on a large pedigree. Genet Epidemiol 1996;13:91‑106.

3. Olshen AB, O'Sullivan F. Camouflaged deconvolution with application to blood curve modeling in FDG PET studies. J Am Stat Association 1997;92:1293‑1303.

4. Eubank WB, Mankoff DA, Schmiedl UP, Winter TC 3rd, Fisher ER, Olshen AB, Graham MM, Eary JF. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy. Am J Roentol 1998;171:1103-1110.

5. Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen AB, Link JM, O'Sullivan F, Krohn KA. 2‑[C‑1 1]Thymidine imaging of malignant brain tumors. Cancer Res 1999;59:615‑621.

6. Olivier et al. (I am the 33rd author out of 56, listed in alphabetical order). A high-resolution radiation hybrid map of the human draft sequence. Science 2001;291:1298‑1302.

7. Wilhelm M, Veltman JA, Olshen AB, Jain AN, Moore DH, Kovacs G, Presti JC, Waldman FM. Array-based CGH for the differential diagnosis of renal cell cancer. Cancer Res 2002;62:957-960.

8. Massion PP, Kuo W-L, Stokoe D, Tressler PA, Olshen AB, Basas J, Chen C, Riedell L, Polikoff D, Jablons DM, Jain AN, Pinkel D, Albertson D, Gray JW. Genome scanning of non-small cell lung cancer using array comparative genomic hybridization: implications of the PI3-kinase pathway." Cancer Res 2002;62:3636-3640.

9. Olshen AB, Jain AN. Deriving quantitative conclusions from microarray expression data. Bioinformatics 2002;18:961-970.

10. Staack A, Kassis AP, Olshen AB, Wang Y, Wu D, Carroll PR, Grossfeld GD, Cunha GR, Hayward SW. Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate 2003;54:212-219.

11. Solit DB, Basso AD, Olshen AB, Scher H, Rosen N. Inhibition of heat-shock-protein-90 function down-regulates Akt kinase and sensitizes tumors to taxol. Cancer Res 2003;63:2139-2144.

12. Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S, Carroll P, Kuo W-L, Pinkel D, Albertson D, Cordon-Cardo C, Jain AN, Waldman FM. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003;63:2872-2880.

13. Hedvat CV, Comenzo RL, Teruya-Feldstein J, Olshen AB, Ely SA, Osman K, Zhang YN, Kalakonda N, Nimer SD. Insights into extramedullary tumor-cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol 2003;122:728-744.

14. Lucito R, Healy J, Alexander J, Reiner A, Esposito D, Chi M, Rodgers L, Brady A, Sebat J, Troge J, West JA, Rostan S, Nguyen KC, Powers S, Ye KQ, Olshen A, Venkatraman E, Norton L, Wigler M. Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res 2003;13:2291-2305.

15. DeCandia P, Solit DB, Giri D, Brogi E, Siegel PM, Olshen AB, Muller WJ, Rosen N, Benezra R. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci 2003;12337-12342.

16. Westermark U, Reyngold M, Olshen AB, Baer R, Jasin M, Moynahan M. BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Mol Cell Biol 2003;23:7926-7936.

17. Bastian BC, Olshen AB, Kashani-Sabet M, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003;1765-1770.

18. Houldsworth J, Olshen AB, Cattoretti G, Donnelly GB, Teruya-Feldstein J, Qin J, Palanisamy N, Shen YJ, Dyomina K, Petlakh M, Pan Q, Zelenetz AD, Dalla-Favera R, Chaganti RSK. REL is not the functional target gene within the 2p12-16 amplicon in diffuse large B-cell lymphomas. Blood 2004;103:1862-1868.

19. Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR, Boyd J. Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol 2004;92:719-725.

20. Couedel C, Mills KD, Marco B, Shen L, Olshen A, Johnson RD, Nussenzweig A, Essers J, Kanaar R, Li GC, Alt FW, Jasin M. Collaboration of homologous recombination and nonhomologous end-joining factors for the survival and integrity of mice and cells. Genes Dev 2004;18:1293-1304.

21. Yoon SS, Segal NH, Olshen AB, Brennan MF, Singer S. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol 2004;15:1261-1266.

22. Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, Dupont J, Hensley M, Sonoda Y, Barakat RR, Anderson S. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 2004;101:1455-1462.

23. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular Binary Segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-572.

24. Ferguson SE, Olshen AB, Viale A, Barakat RR, Boyd J. Stratification of intermediate-risk endometrial cancer patients into groups at high risk or low risk for recurrence based on tumor gene expression profiles. Clin Cancer Res 2005;11:2252-2257.

25. Chadalavada RS, Houldsworth J, Olshen AB, Bosl GJ, Studer L, Chaganti RS. Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent human embryonal carcinoma cells. Funct Integr Genomics 2005;5:59-69.

26. Korkola JE, Houldsworth J, Dobrzynski D, Olshen AB, Reuter VE, Bosl GJ, Chaganti RS. Gene expression-based classification of nonseminomatous male germ cell tumors. Oncogene 2005;24(32):5101-7.

27. Olshen AB, Cosman PC, Rodrigo AG, Bickel PJ, Olshen RA. Vector quantization of amino acids: analysis of the HIV V3 loop region. Journal of Statistical Planning and Inference 2005;130:277-98.

28. Huang S, Li Y, Podsypanina K, Chamorro M, Olshen AB, Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice. Genome Biol. 2005;6(10): R84, Epub 2005 Sep 30.

29. Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordon-Cardo C, Olshen AB, Gerald WL, Massague J. Identifying Site-specific Metastasis Genes and Functions. Cold Spring Harb Symp Quant Biol. 2005;70:1-10.

30. Moskowitz CH, Zelenetz AD, Kewalramani T, Hamlin P, Lessac-Chenen S, Houldworth J, Olshen A, Chaganti R, Nimer S. Cell of orgin , germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed an refractor DLBCL. Blood. 2005;106(10):3383-5.

31. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature. 2005 Jul 28;436(7050):518-24.

32. Leliser AL, Anderson SE, Nonaka D, Chuai S, Olshen AB, Chi DS, Apoptotic and cell cycle regulatory markers in uterine leiomyosarcomas. Gynecol Oncol. 2006;101(1):86-91.

33. Ferguson SE, Olshen AB, Levine DA, Viale A, Barakat RR, Boyd J. Molecular profiling of endometrial cancers from African-American and Caucasian women. 2006 Gynecol Oncol. 2006;101(2):209-13.

34. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116(1):271-84.

35. Korkola JE, Houldsworth J, Chadalavada RS, Olshen AB, Dobrzynski D, Reuter VE, Bosl GJ, Chaganti RS. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res. 2006;66(2):820-7.

36. Chen W, Houldsworth J, Olshen AB, Nabjangud G, Chaganti S, Venkatraman ES, Halaas J, Teruya-Feldstein J, Zelenetz AD, Chaganti RS. Array comparative genomic hybrization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood 2006;107(6):2477-85.

37. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, Illei PB, Hussain S, Krug L, Zakowski MF, Rusch V, Olshen AB, Ladanyi M. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. 1: Cancer Res. 2006;66(6):2970-9.

38. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, McLennan J, Ziegler J, Chin K, Devries S, Feiler H, Gray JW, Waldman F, Pinkel D, Albertson DG. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer. 2006;6:96.

39. Anderson SE, Nonaka D, Chuai S, Olshen AB, Chi D, Sabbatini P, Soslow RA. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas. Int J Gynecol Cancer. 2006;16(2):849-53.